Abstract
Pemetrexed is a multitarget antifolate agent used to treat recurrent non-small cell lung cancer (NSCLC) after prior platinum-based chemotherapy. In a large phase III study, compared with docetaxel, pemetrexed was shown to have similar response rates and disease stabilization, with a better safety profile.1 Pemetrexed has not been considered as a cause of acute lung injury. However, here, we present a case of acute lung injury associated with pemetrexed in a patient with metastatic patient.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
